cifenline has been researched along with atenolol in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Mahmood, I | 1 |
| Miida, T; Mitsuma, K; Oda, H; Ozaki, K; Sakuma, I; Suzuki, T; Takahashi, K; Tsuchida, K | 1 |
| Doi, YL; Kitaoka, H; Kubo, T; Okawa, M; Tamura, S; Terauchi, Y; Yabe, T; Yamasaki, N | 1 |
8 other study(ies) available for cifenline and atenolol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Prediction of absolute bioavailability for drugs using oral and renal clearance following a single oral dose: a critical view.
Topics: Acebutolol; Administration, Oral; Adult; Aged; Amiloride; Anti-Arrhythmia Agents; Anti-Infective Agents; Area Under Curve; Atenolol; Biological Availability; Diuretics; Enoxacin; Flecainide; Histamine H2 Antagonists; Humans; Imidazoles; Kidney; Middle Aged; Ranitidine; Renal Insufficiency; Tiopronin | 1997 |
Effect of cibenzoline and atenolol administration on dynamic left ventricular obstruction due to sigmoid-shaped septum.
Topics: Adrenergic beta-Antagonists; Aged; Aging; Anti-Arrhythmia Agents; Atenolol; Blood Pressure; Drug Therapy, Combination; Dyspnea; Echocardiography, Doppler; Electrocardiography; Exercise Test; Exercise Tolerance; Heart Septum; Humans; Imidazoles; Male; Middle Aged; Treatment Outcome; Ventricular Function, Left; Ventricular Outflow Obstruction; Ventricular Pressure | 2008 |
Hemolytic anemia in a patient with hypertrophic obstructive cardiomyopathy.
Topics: Aged; Anemia, Hemolytic; Anti-Arrhythmia Agents; Atenolol; Cardiomyopathy, Hypertrophic; Echocardiography; Female; Humans; Imidazoles; Mitral Valve Insufficiency; Ventricular Outflow Obstruction | 2010 |